Philpott Andrew C, Southern Danielle A, Clement Fiona M, Galbraith P Diane, Traboulsi Mouhieddin, Knudtson Merril L, Ghali William A
Department of Medicine, University of Calgary, Calgary, Alberta.
CMAJ. 2009 Jan 20;180(2):167-74. doi: 10.1503/cmaj.080050. Epub 2008 Dec 18.
We sought to establish the long-term safety of drug-eluting stents compared with bare-metal stents in a usual care setting.
Using data from a prospective multicentre registry, we compared rates of death and of death or repeat revascularization during 3 years of follow-up of 6440 consecutive patients who underwent angioplasty with either drug-eluting or bare-metal stents between Apr. 1, 2003, and Mar. 31, 2006.
Drug-eluting stents were inserted in 1120 patients and bare-metal stents in 5320. The drug-eluting stents were selected for patients who had a greater burden of comorbid illness, including diabetes mellitus (32.8% v. 20.8% in the bare-metal group, p < 0.001) and renal disease (7.4% v. 5.0%, p = 0.001). At 1-year follow-up, the drug-eluting stents were associated with a mortality of 3.0%, as compared with 3.7% with the bare-metal stents (adjusted odds ratio [OR] 0.62, 95% confidence interval [CI] 0.46-0.83). The rate of the composite outcome of death or repeat revascularization was 12.0% for the drug-eluting stents and 15.8% for the bare-metal stents (adjusted OR 0.40, 95% CI 0.33-0.49). In the subgroup of patients who had acute coronary syndromes, the adjusted OR for this composite outcome was 0.46 (95% CI 0.35-0.61). During the 3 years of observation, the relative risks for death and repeat revascularization varied over time. In year 1, there was an initial period of lower risk in the group with drug-eluting stents than in the group with bare-metal stents; this was followed by a shift toward outcome rates favouring bare-metal stents in years 2 and 3. The adjusted relative risk of the composite outcome of death or repeat revascularization associated with drug-eluting stents relative to bare-metal stents was 0.73 early in the first year of follow-up; it then rose gradually over time, to a peak of 2.24 at 3 years.
Drug-eluting stents are safe and effective in the first year following insertion. Thereafter, the possibility of longer term adverse events cannot be ruled out.
我们试图在常规治疗环境中确定药物洗脱支架与裸金属支架相比的长期安全性。
利用一项前瞻性多中心注册研究的数据,我们比较了2003年4月1日至2006年3月31日期间连续6440例接受药物洗脱支架或裸金属支架血管成形术患者在3年随访期间的死亡率以及死亡或再次血管重建率。
1120例患者植入了药物洗脱支架,5320例患者植入了裸金属支架。药物洗脱支架用于合并症负担较重的患者,包括糖尿病(32.8%对裸金属组的20.8%,p<0.001)和肾病(7.4%对5.0%,p=0.001)。在1年随访时,药物洗脱支架的死亡率为3.0%,而裸金属支架为3.7%(调整后的优势比[OR]0.62,95%置信区间[CI]0.46 - 0.83)。药物洗脱支架的死亡或再次血管重建复合结局发生率为12.0%,裸金属支架为15.8%(调整后的OR 0.40,95%CI 0.33 - 0.49)。在急性冠状动脉综合征患者亚组中, 该复合结局的调整后OR为0.46(95%CI为0.35 - 0.61)。在3年观察期内,死亡和再次血管重建的相对风险随时间变化。在第1年,药物洗脱支架组有一个初始低风险期,低于裸金属支架组;随后在第2年和第3年出现有利于裸金属支架的结局率转变。在随访第1年早期,与裸金属支架相比,药物洗脱支架相关的死亡或再次血管重建复合结局的调整后相对风险为0.73;然后随时间逐渐上升,在3年时达到峰值2.24。
药物洗脱支架在植入后的第1年是安全有效的。此后,不能排除长期不良事件的可能性。